miR-132 may also regulate tau alternative splicing in vitro by targeting poly-pyrimidine tract-binding protein 2 (PTBP2), and its levels correlate with tau splicing defects in patients with progressive supranuclear palsy (PSP) cases (Smith et al., 2011). This evidence concerns the gene MAPT and progressive supranuclear palsy.